Navigation Links
Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin ('PedPRM') to be Marketed by Biocodex in France
Date:3/13/2017

TEL AVIV, Israel, March 13, 2017 /PRNewswire/ --

Neurim Pharmaceuticals ('Neurim') announced today that it has entered into a licensing agreement with Biocodex. The agreement grants Biocodex exclusive marketing rights for Neurim's new Rx PedPRM in France.

Neurim's age-appropriate drug is targeted to treat sleep disorders in children with autism spectrum disorders (ASD) and neurogenetic diseases. It is expected to be the first sleep drug approved for children.

Biocodex promotes Circadin®, prolonged-release melatonin 2mg, indicated to treat primary insomnia in the elderly, since 2013 in France. "Biocodex played a significant role in obtaining reimbursement for Circadin under a Temporary Recommendation for Use (RTU) for treating sleep disorders in children with neurodevelopmental disorders. It was only natural that the collaboration will deepen to include PedPRM," said Sharon Elkobi, VP Business Development of Neurim Pharmaceuticals. "Additional agreements are expected to follow in order to make the new treatment accessible for children and their families."

"Sleep disturbances in children presenting with neurodevelopment disabilities represent an unresolved therapeutic challenge. In addition to Circadin® for the treatment of primary insomnia in adults, Biocodex is pleased to expand its productive partnership with Neurim and is proud to continue the work being done on the RTU in order to make this new promising product available for these children in France," said Paul Bernasconi, MD, Vice President France Operations of Biocodex.

About PedPRM 

PedPRM is a response to an unmet clinical need in the field of paediatric insomnia, specifically developed to address main concerns in children with ASD and neurogenetic diseases. PedPRM is an age-appropriate formulation designed for populations with swallowing difficulties.

PedPRM has recently completed a Phase III study, under EU-PIP and US-FDA IND, showing positive top-line results. The drug met the primary efficacy endpoint demonstrating statistically significant improvement in total sleep time (TST) compared to placebo. Secondary efficacy endpoints demonstrating improvements in sleep initiation and maintenance were met as well.

About Neurim Pharmaceuticals

Neurim Pharmaceuticals Ltd. (http://www.neurim.com) is a neuroscience drug discovery and development company. Its first approved drug Circadin® is commercially available in Europe, Asia-Pacific, Latin America, Africa and the Middle East.

The company has a strong and innovative product pipeline intended for insomnia, Alzheimer's disease, dementia, glaucoma and pain.

Contact:
Sharon Elkobi
VP Business Development
sharone@neurim.com


'/>"/>
SOURCE Neurim Pharmaceuticals Ltd.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Australia and New Zealand
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
4. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
5. Access Pharmaceuticals Reports First Quarter Results
6. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
7. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
8. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
9. Aveo Pharmaceuticals, Inc. Sued by Investor
10. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
11. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2018)... ... August 07, 2018 , ... ... appointment of Richard A. Stark to assume the role of Sanarus Technologies President, effective immediately. ... years of strategic development, marketing and sales experience in medical device toward finding new ...
(Date:8/3/2018)... ... ... In order to improve safety for everyone throughout the summer, personal injury ... risks of injury that many amusement park rides present during the summer months. ... thrilling ride on a roller coaster. Unfortunately, these fun times can quickly turn dangerous ...
(Date:8/2/2018)... ... August 02, 2018 , ... ... gummy smile for custom crown lengthening treatment at his Eden Prairie, ... line and an unsteady self-conscious. Using decades of experience, Dr. Sanchez is excited ...
Breaking Medicine Technology:
(Date:8/9/2018)... ... August 09, 2018 , ... ... engaged as an Operating Partner and will have an exclusive relationship with the ... in the firm’s strategic planning, human capital sourcing, and deal origination, evaluation and ...
(Date:8/7/2018)... ... August 07, 2018 , ... The American Psychiatric ... to receive the 2018 Board of Directors Student Scholarship . The APNA ... psychiatric-mental health nursing and develop the next generation of leaders in the profession. ...
(Date:8/2/2018)... ... 2018 , ... Dr. Srini Pillay , best-selling author of TINKER ... could care less, demonstrating a “whatever” attitude toward life, people, and situations around them. ... often overlooked reason relates to being overworked. Called self-regulation depletion (SRD), this condition occurs ...
(Date:8/2/2018)... ... August 02, 2018 , ... A ... of topics in acute pain management. In The Role of Acute Care in ... Prescribing Engagement Network—an innovative approach to the opioid epidemic launched in the state ...
(Date:8/2/2018)... ... August 02, 2018 , ... Tunstall Americas has launched their ... can partner with Tunstall Americas for After-hours call-handling, Overflow call-handling, and Appointment Scheduling ... expand their suite of Patient Access Solutions, and gives their existing and new ...
Breaking Medicine News(10 mins):